IkT-148009 for Parkinson’s Disease and GI complications of Parkinson’s Patients

Disease-Modifying Therapy to Reverse the Course of Parkinson’s Disease

Our lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule medication designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of reversing disease progression. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to prevent and/or reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.

Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in the brain and GI tract in animal models using IkT-148009, we submitted two Investigational New Drug (IND) applications February, 2019, to begin clinical development in multiple classes of Parkinson’s patients. Clinical development should proceed at the end of the 1Q19.

Back to Top